There were 1,558 press releases posted in the last 24 hours and 405,917 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.